GRP
VRDN icon

Global Retirement Partners’s Viridian Therapeutics VRDN Stock Holding History

Global Retirement Partners’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3.02K Buy
97
+84
+646% +$2.3K ﹤0.01% 3596
2025
Q3 		$281 Hold
13
– – ﹤0.01% 3712
2025
Q2 		$182 Buy
+13
New +$176 ﹤0.01% 3678

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Global Retirement Partners's VRDN Position: Q4 2025 in Review

Global Retirement Partners increased its Viridian Therapeutics (VRDN) stake by 646% in Q4 2025, buying an estimated $2.3K and bringing the position to 97 shares worth $3.02K. The position accounts for ﹤0.01% of the portfolio, ranked #3596.

Global Retirement Partners first reported a position in VRDN in Q2 2025 and has held it in 3 quarters since. 229 funds tracked by Wall St. Rank hold VRDN as of Q4 2025.

  • Global Retirement Partners held 97 shares of Viridian Therapeutics worth $3.02K as of Q4 2025.
  • Global Retirement Partners bought 84 Viridian Therapeutics shares in Q4 2025, an estimated $2.3K.
  • Viridian Therapeutics made up ﹤0.01% of Global Retirement Partners's portfolio in Q4 2025, its #3596 holding.
  • Global Retirement Partners first reported a position in Viridian Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 229 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2025.

Based on Global Retirement Partners's 13F filing for Q4 2025, filed 6 Feb 2026.